Ambrx Biopharma Inc
NYSE:AMAM
Relative Value
The Relative Value of one AMAM stock under the Base Case scenario is 0.64 USD. Compared to the current market price of 28 USD, Ambrx Biopharma Inc is Overvalued by 98%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Valuation Multiples
Multiples Across Competitors
AMAM Competitors Multiples
Ambrx Biopharma Inc Competitors
Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
---|---|---|---|---|---|---|---|---|
US |
A
|
Ambrx Biopharma Inc
NYSE:AMAM
|
1.8B USD | 312 | -21.4 | -17.9 | -17.5 | |
US |
Abbvie Inc
NYSE:ABBV
|
288.7B USD | 5.3 | 59.9 | 13 | 19.8 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
147.9B USD | 5.2 | 22 | 16.4 | 24.5 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
103B USD | 10.4 | 28.5 | 22.8 | 23.8 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
98.5B USD | 7.5 | 24.9 | 16.5 | 18.2 | ||
AU |
CSL Ltd
ASX:CSL
|
132.6B AUD | 6.1 | 35 | 21.2 | 26.3 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
81.6B USD | 3 | 14.4 | 7.9 | 10.2 | ||
US |
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | ||
US |
Moderna Inc
NASDAQ:MRNA
|
41.7B USD | 6.1 | -8.8 | -9.3 | -7.9 | ||
US |
Biogen Inc
NASDAQ:BIIB
|
31.3B USD | 3.2 | 27 | 14.6 | 18.1 | ||
KR |
Celltrion Inc
KRX:068270
|
39.2T KRW | 18 | 73.1 | 44.7 | 61.6 |